Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Cardio Diagnostics Holdings ( (CDIO) ) just unveiled an update.
Cardio Diagnostics Holdings, Inc. announced a 1-for-30 reverse stock split of its common stock, effective after the close of trading on May 12, 2025, with trading on a post-split basis beginning on May 13, 2025. This move, approved by the stockholders in November 2024, aims to help the company regain compliance with Nasdaq’s minimum bid price requirement, reducing the number of outstanding shares from approximately 52 million to 1.7 million while maintaining the number of authorized shares at 300 million.
The most recent analyst rating on (CDIO) stock is a Buy with a $2.00 price target. To see the full list of analyst forecasts on Cardio Diagnostics Holdings stock, see the CDIO Stock Forecast page.
More about Cardio Diagnostics Holdings
Cardio Diagnostics Holdings, Inc. is an artificial intelligence-powered precision cardiovascular medicine company focused on making cardiovascular disease prevention, detection, and management more accessible, personalized, and precise. The company leverages its proprietary AI-driven Integrated Genetic-Epigenetic Engine to develop and commercialize clinical tests aimed at improving the prevention, detection, and treatment of cardiovascular disease.
Average Trading Volume: 38,964
Technical Sentiment Signal: Sell
Current Market Cap: $8.2M
See more data about CDIO stock on TipRanks’ Stock Analysis page.